Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Acad Pathol ; 7: 2374289520958200, 2020.
Article in English | MEDLINE | ID: mdl-33088910

ABSTRACT

When South Florida became a hot spot for COVID-19 disease in March 2020, we faced an urgent need to develop test capability to detect SARS-CoV-2 infection. We assembled a transdisciplinary team of knowledgeable and dedicated physicians, scientists, technologists, and administrators who rapidly built a multiplatform, polymerase chain reaction- and serology-based detection program, established drive-through facilities, and drafted and implemented guidelines that enabled efficient testing of our patients and employees. This process was extremely complex, due to the limited availability of needed reagents, but outreach to our research scientists and multiple diagnostic laboratory companies, and government officials enabled us to implement both Food and Drug Administration authorized and laboratory-developed testing-based testing protocols. We analyzed our workforce needs and created teams of appropriately skilled and certified workers to safely process patient samples and conduct SARS-CoV-2 testing and contact tracing. We initiated smart test ordering, interfaced all testing platforms with our electronic medical record, and went from zero testing capacity to testing hundreds of health care workers and patients daily, within 3 weeks. We believe our experience can inform the efforts of others when faced with a crisis situation.

2.
Clin Cancer Res ; 15(15): 4944-53, 2009 Aug 01.
Article in English | MEDLINE | ID: mdl-19602548

ABSTRACT

PURPOSE: The therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myeloid malignancies has been attributed in part to a graft-versus-leukemia effect that is dependent on donor T lymphocytes. CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood. EXPERIMENTAL DESIGN: We examined the diversity, phenotype, and functional potential of leukemia-associated antigen-specific CD8(+) T cells in patients with myeloid leukemia following allogeneic HSCT. Screening for antigen-specific T cells was accomplished with a peptide/MHC tetramer library. RESULTS: Patients with acute myelogenous leukemia or chronic myelogenous leukemia in remission following HSCT exhibited significant numbers of peripheral blood CD8(+) T cells that recognized varying combinations of epitopes derived from leukemia-associated antigens. However, these cells failed to proliferate, release cytokines, or degranulate in response to antigen-specific stimuli. As early as 2 months after HSCT, CD8(+) T cells from patients were predominantly CD28(-) CD57(+) and had relatively short telomeres, consistent with cellular senescence. CONCLUSIONS: Circulating leukemia-specific CD8(+) T cells are prominent in myeloid leukemia patients after HSCT, but such cells are largely functionally unresponsive, most likely due to replicative senescence. These findings carry important implications for the understanding of the graft-versus-leukemia effect and for the rational design of immunotherapeutic strategies for patients with myeloid leukemias.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cellular Senescence/immunology , Graft vs Leukemia Effect/immunology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Leukemia, Myeloid, Acute/surgery , Stem Cell Transplantation , Adult , Aged , Antigens, CD/immunology , Antigens, CD/metabolism , Apoptosis Regulatory Proteins/immunology , Apoptosis Regulatory Proteins/metabolism , CD8-Positive T-Lymphocytes/metabolism , Female , Humans , Interferon-gamma/immunology , Interferon-gamma/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Leukemia, Myeloid, Acute/immunology , Lysosomal-Associated Membrane Protein 1/immunology , Lysosomal-Associated Membrane Protein 1/metabolism , Middle Aged , Programmed Cell Death 1 Receptor , Telomere/immunology , Young Adult
3.
Biol Blood Marrow Transplant ; 14(3): 290-300, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18275895

ABSTRACT

Because natural killer (NK) cells can be potent anti-tumor effectors after allogeneic stem cell transplantation, we investigated NK reconstitution and receptor expression in patients undergoing allogeneic hematopoietic stem cell transplantation, focusing on the activating receptors that trigger anti-tumor responses. We determined that NK levels in the peri-transplant period were inversely proportional to the dramatic rise and fall in plasma levels of the NK homeostatic cytokine IL-15, which increased more than 50-fold from pretreatment to the day of transplant during the lymphoreductive preparative regimen. Furthermore, in NK cells cultured with IL-15, we observed an up-regulation of the activating receptors NKG2D, NKp30, and NKp46, associated with an increase in anti-tumor lytic activity. Similarly, the expression of these activating receptors increased significantly during the early post-transplant period, concurrent with a rapid increase in total NK cells and a shift toward increased expression of CD56. These data suggest that the cytokine milieu of transplants, in particular elevated levels of IL-15, may contribute to anti-tumor efficacy post-transplant by enhancing the recovery of NK subsets and modulating expression of activating receptors.


Subject(s)
Graft vs Leukemia Effect/immunology , Hematopoietic Stem Cell Transplantation , Interleukin-15/immunology , Killer Cells, Natural/immunology , Receptors, Immunologic/immunology , Adult , Aged , CD56 Antigen/biosynthesis , CD56 Antigen/immunology , Cells, Cultured , Female , Graft vs Leukemia Effect/drug effects , Humans , Interleukin-15/blood , Interleukin-15/pharmacology , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Lymphocyte Depletion , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/immunology , Lymphoproliferative Disorders/pathology , Lymphoproliferative Disorders/therapy , Male , Middle Aged , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/pathology , Myelodysplastic Syndromes/therapy , NK Cell Lectin-Like Receptor Subfamily K , Natural Cytotoxicity Triggering Receptor 1 , Natural Cytotoxicity Triggering Receptor 3 , Primary Myelofibrosis/blood , Primary Myelofibrosis/immunology , Primary Myelofibrosis/pathology , Primary Myelofibrosis/therapy , Receptors, Immunologic/biosynthesis , Receptors, Natural Killer Cell , Transplantation, Homologous , Up-Regulation/drug effects , Up-Regulation/immunology
4.
J Neuroimmunol ; 193(1-2): 173-82, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18053582

ABSTRACT

Paraneoplastic cerebellar degeneration (PCD) is linked to an immune response against cerebellar degeneration related antigen 2 (cdr2) co-expressed in tumor and Purkinje neurons. Here, comprehensive immune-assessment assays were used to analyze CD8(+) T cells from 7 PCD patients, but no evidence was found of CD8(+) T cells specific for either of two previously described cdr2 epitopes (cdr2-1 and cdr2-2). In contrast, viral-specific CD8(+) T cells from healthy volunteers and PCD patients were measurable. These findings are inconsistent with an obligate role for cdr2-1- or cdr2-2-specific CD8(+) T cells in the pathogenesis of PCD.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Nerve Tissue Proteins/immunology , Paraneoplastic Cerebellar Degeneration/immunology , Adult , Aged , Female , HLA-A2 Antigen/metabolism , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , Lysosomal-Associated Membrane Protein 1/analysis , Middle Aged , Nerve Tissue Proteins/metabolism , Paraneoplastic Cerebellar Degeneration/etiology , Tumor Necrosis Factor-alpha/biosynthesis
5.
Cancer Biol Ther ; 6(12): 1991-6, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18087213

ABSTRACT

The human telomerase reverse transcriptase hTERT is overexpressed in most human tumors and contributes importantly to oncogenesis by maintaining the integrity of telomeric DNA. Despite being a self-antigen, the hTERT enzyme is immunogenic. Peptides derived from hTERT have been shown both in vitro and in vivo to drive the activation and proliferation of peptide-specific T lymphocytes. An HLA-A2-binding peptide from Htert (I540, ILAKFLHWL) has been used to generate peptide-specific T cells in vitro and in vivo in patients that lyse telomerase-positive tumors in an MHC-restricted fashion. Although these and other data suggest that I540 is naturally processed and presented on the surface of certain tumor cells, there are reports that I540-specific T cells, and in particular, T cell clones, do not lyse tumors in vitro. Here, we compared cytotoxic function of I540-specfic T cell clones vs. polyclonal T cell lines, including clones and lines generated from the same donor. We found that I540-specific polyclonal T cell lines lyse telomerase-positive tumors whereas non-specific polyclonal T cell lines and I540-specific T cell clones do not. Estimated TCR avidity for I540, as well as cell surface expression of CD45RO, CD45RA, CD28, CD27, CD57 and CD62L were similar between lines and clones. V beta usage, however, differed such that the majority of the I540-specific TCR repertoire found in polyclonal T cell lines was not represented in clones generated from the same source material. Thus, I540-specific T cells can vary in cytotoxic potential depending on the method of generation, isolation and expansion.


Subject(s)
Neoplasm Proteins/immunology , Peptide Fragments/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Cell Antigen Receptor Specificity , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Cytotoxic/immunology , Telomerase/immunology , Antigens, CD/analysis , Antigens, Neoplasm/analysis , Cancer Vaccines/immunology , Cell Line, Tumor/immunology , Clone Cells/immunology , Cytotoxicity, Immunologic , Dendritic Cells/immunology , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , HLA-A2 Antigen/immunology , Humans , Immunodominant Epitopes/immunology , K562 Cells/immunology , K562 Cells/radiation effects , Receptors, Antigen, T-Cell, alpha-beta/genetics
6.
Cancer Res ; 67(21): 10546-55, 2007 Nov 01.
Article in English | MEDLINE | ID: mdl-17974999

ABSTRACT

The human telomerase reverse transcriptase (hTERT) is nearly universally overexpressed in human cancer, contributes critically to oncogenesis, and is recognized by cytotoxic T cells that lyse tumors. CD8+ T cells specific for hTERT naturally occur in certain populations of cancer patients in remission, but it remains poorly understood whether such T cells could contribute to tumor immunosurveillance. To address this issue, we induced hTERT-specific T cells in vivo via peptide vaccination in 19 patients with metastatic breast cancer who otherwise had no measurable T-cell responses to hTERT at baseline. Tumor-infiltrating lymphocytes (TIL) were evident after, but not before vaccination, with 4% to 13% of postvaccine CD8+ TIL specific for the immunizing hTERT peptide. Induction of TIL manifested clinically with tumor site pain and pruritus and pathologically with alterations in the tumor microenvironment, featuring histiocytic accumulation and widespread tumor necrosis. hTERT-specific CD8+ T cells were also evident after vaccination in the peripheral blood of patients and exhibited effector functions in vitro including proliferation, IFN-gamma production, and tumor lysis. An exploratory landmark analysis revealed that median overall survival was significantly longer in those patients who achieved an immune response to hTERT peptide compared with patients who did not. Immune response to a control cytomegalovirus peptide in the vaccine did not correlate with survival. These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer.


Subject(s)
Breast Neoplasms/immunology , Cancer Vaccines/immunology , T-Lymphocytes/immunology , Telomerase/immunology , Vaccination , Adult , Aged , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Cytomegalovirus/immunology , Female , Humans , Lymphocytes, Tumor-Infiltrating/pathology , Middle Aged
7.
Gastroenterology ; 132(2): 654-66, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17258733

ABSTRACT

BACKGROUND & AIMS: Acute hepatitis C virus (HCV) infection becomes chronic in the majority of patients. Although HCV-specific CD4 T-cell response is associated with HCV clearance, less is known about virus-specific CD8 T-cell or neutralizing antibody (nAb) responses and the role of CD4 help in their induction during acute infection. METHODS: HCV-specific CD4, CD8, and HCV pseudoparticle (HCVpp) nAb responses were monitored in acutely HCV-infected patients to define their relative contributions to viral clearance. RESULTS: Our results show that the outcome of acute hepatitis C is associated with a functional hierarchy in HCV-specific CD4 T-cell response and the scope of virus-specific, total T-cell interferon-gamma response. HCV-specific CD8 T-cell response was readily detectable in acutely HCV-infected patients regardless of virologic outcome or virus-specific CD4 T-cell response. In contrast, HCVpp-specific nAbs were readily detected in patients with chronic evolution and impaired virus-specific CD4 T-cell response but not in patients who cleared infection with robust virus-specific CD4 T-cell response. CONCLUSIONS: The outcome of acute hepatitis C is associated with efficient virus-specific CD4 T-cell response(s) without which HCV-specific CD8 T-cell and heterologous nAb responses may develop but fail to clear viremia. Furthermore, HCV-specific nAb responses may not be induced despite robust virus-specific CD4 T-cell response.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Hepacivirus/immunology , Hepatitis C Antibodies/blood , Hepatitis C/immunology , Acute Disease , Adult , Aged , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/virology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/virology , Female , Follow-Up Studies , Hepacivirus/genetics , Hepatitis C/metabolism , Hepatitis C/virology , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/virology , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , Male , Middle Aged , Prognosis , RNA, Viral/blood , Time Factors , United States , Virion/immunology
8.
J Clin Oncol ; 24(36): 5725-34, 2006 Dec 20.
Article in English | MEDLINE | ID: mdl-17179106

ABSTRACT

PURPOSE: Tumor immunosurveillance influences oncogenesis and tumor growth, but it remains controversial whether clinical failure of immunosurveillance is a result of lymphocyte dysfunction or tumor escape. In this study, our goal was to characterize the physiology of tumor immunosurveillance in children with high-risk neuroblastoma (HR-NBL). PATIENTS AND METHODS: Immunohistopathologic studies were carried out on 26 tumor samples from a cohort of HR-NBL patients diagnosed at Children's Hospital of Philadelphia for the 2-year period from May 2003 to May 2005. Blood from nine HLA-A2+ patients in this cohort was analyzed for T cells specific for the antiapoptotic protein survivin. RESULTS: Survivin protein was expressed by 26 of 26 tumors. In HLA-A2+ patients, circulating cytotoxic T lymphocytes (CTLs) specific for survivin were detected by peptide/major histocompatibility complex tetramer analysis in the blood of eight of nine children with HR-NBL at the time of diagnosis. Rather than being selectively rendered anergic in vivo, circulating survivin-specific CTLs were highly functional as shown by cytotoxicity and interferon gamma enzyme-linked immunospot assays in six of nine patients. Survivin-specific CD107a mobilization by T cells was found in five of five patients. By immunohistochemistry, tumor-infiltrating T cells were few or absent in 26 of 26 tumors. CONCLUSION: Children with HR-NBL harbor robust cellular immune responses to the universal tumor antigen survivin at the time of diagnosis, but intratumoral T cells are strikingly rare, suggesting a failure of cellular immunosurveillance. Efforts to develop novel therapies that increase T-cell trafficking into tumor nests are warranted.


Subject(s)
Immunologic Surveillance , Lymphocytes, Tumor-Infiltrating/immunology , Microtubule-Associated Proteins/metabolism , Neoplasm Proteins/metabolism , Neuroblastoma/immunology , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Immunohistochemistry , Infant , Inhibitor of Apoptosis Proteins , Male , Risk Factors , Survivin
9.
Arch Biochem Biophys ; 438(1): 11-20, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15893733

ABSTRACT

CD69 is thought to be a pluripotent signaling molecule expressed on the surface of a number of activated leukocytes including B, T, and NK cells, monocytes, neutrophils, and platelets. While some advances have been made regarding the mechanisms by which CD69 may participate in such diverse functions as cell aggregation, cellular cytotoxicity, and release of cytokines and inflammatory mediators, the most proximal links of signal initiation have not been identified. Our study has identified, by immunoprecipitation and direct protein sequencing (LC/MS/MS), binding of CD69 to an N-terminal protein fragment of calreticulin expressed on the cell surface of human PBMCs. Given the recently identified roles calreticulin plays in cell adhesion and angiogensis, the identification of CD69 binding directly to calreticulin may provide insights into mechanism(s) by which CD69 or other CD69 family members, i.e., LLT1 and AICL participates in such diverse functions.


Subject(s)
Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/metabolism , Calreticulin/metabolism , Cell Communication/physiology , Cell Membrane/metabolism , Leukocytes, Mononuclear/metabolism , Protein Interaction Mapping/methods , Amino Acid Sequence , Antigens, CD/chemistry , Antigens, Differentiation, T-Lymphocyte/chemistry , Binding Sites , Calreticulin/chemistry , Cells, Cultured , Humans , Lectins, C-Type , Molecular Sequence Data , Protein Binding
10.
J Clin Invest ; 115(4): 930-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15776111

ABSTRACT

Homeostatic regulation of T cells involves an ongoing balance of new T cell generation, peripheral expansion, and turnover. The recovery of T cells when this balance is disrupted provides insight into the mechanisms that govern homeostasis. In a long-term, single cohort study, we assessed the role of thymic function after autologous transplant in adults, correlating serial computed tomography imaging of thymic size with concurrent measurements of peripheral CD4(+) T cell populations. We established the age-dependent incidence, time course, and duration of thymic enlargement in adults and demonstrated that these changes were correlated with peripheral recovery of naive CD45RA(+)CD62L(+) and signal-joint TCR rearrangement excision circle-bearing CD4(+) populations with broad TCR diversity. Furthermore, we demonstrated that renewed thymopoiesis was critical for the restoration of peripheral CD4(+) T cell populations. This recovery encompassed the recovery of normal CD4(+) T cell numbers, a low ratio of effector to central memory cells, and a broad repertoire of TCR Vbeta diversity among these memory cells. These data define the timeline and consequences of renewal of adult thymopoietic activity at levels able to quantitatively restore peripheral T cell populations. They further suggest that structural thymic regrowth serves as a basis for the regeneration of peripheral T cell populations.


Subject(s)
CD4-Positive T-Lymphocytes/physiology , Homeostasis , Thymus Gland/cytology , Thymus Gland/physiology , Adult , Age Factors , Aged , Breast Neoplasms/pathology , Cohort Studies , Female , Humans , Leukocyte Common Antigens/metabolism , Middle Aged , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/metabolism , Statistics as Topic , Thymus Gland/transplantation , Time Factors , Transplantation, Autologous
11.
Int J Oncol ; 24(4): 861-7, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15010823

ABSTRACT

Breast cancer cells pose a difficult target for detection due to their lack of tumor specific markers. Small numbers of metastatic cells circulate through the blood and reach target organs, but current methods are presently not sensitive enough to allow for early detection. Our goal is to develop a method for specific and sensitive detection for breast cancer tumor cells by using cell enrichment coupled to RT-PCR with selective primer pairs. Fifty million normal donor mononuclear cells (NDMNC) were spiked with serial dilutions of a breast cancer cell line, positively selected for surface expression of the epithelial cell adhesion molecule (EPCAM) with anti-Ber-EP4 mAb. Total RNA was isolated and the cDNA was transcribed and measured by quantitative PCR for cytokeratin 19 (CK19), epidermal growth factor receptor (EGF-R), and beta-2-microglobulin (beta2M) transcripts using specific hybridization probes with the LightCycler System. A sensitivity of 1 tumor cell in 5 million NDMNC was consistently achieved with a metastatic breast cancer cell line with target primer sets for CK19 and EGF-R. Less, but appreciable sensitivity was achieved by spiking NDMNC with other breast cancer cells. Detection of both gene targets ranged between 1 in 5,000 to 5 million cells. The method described, a cell enrichment procedure and RT-PCR using specific hybridization probes (spanning introns and hybridizing to areas that discriminate transcribed pseudogenes), results in increased sensitivity while decreasing false positives above those methods previously reported. This general approach may have wide applicability to increasing sensitivity of minimal residual disease detection in other cancers.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , DNA, Neoplasm/analysis , ErbB Receptors/genetics , Keratins/genetics , Breast Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Neoplasm, Residual , RNA, Neoplasm/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Tumor Cells, Cultured , beta 2-Microglobulin/genetics
12.
Blood ; 103(6): 2046-54, 2004 Mar 15.
Article in English | MEDLINE | ID: mdl-14630810

ABSTRACT

Vaccination with antigen-presenting cells (APCs) engineered to mimic mechanisms of immune stimulation represents a promising approach for cancer immunotherapy. Dendritic cell vaccines have entered phase 3 testing in adult malignancies, but such vaccines in children have been limited. We demonstrate that CD40-activated B cells (CD40-B) transfected with RNA may serve as an alternative vaccine that can be generated from small blood volumes regardless of patient age. CD40-B from pediatric patients are efficient APCs and can be loaded with RNA as an antigenic payload, permitting simultaneous targeting of multiple antigenic epitopes without the necessity of HLA matching. For viral and tumor antigens, CD40-B/RNA technology induced cytotoxic T lymphocytes (CTLs) from adults and children, which could be identified with peptide/major histocompatibility complex (MHC) tetramers. These CTLs secreted interferon-gamma (IFN-gamma) and killed targets in an MHC-restricted fashion. For pooled neuroblastoma RNA and autologous neuroblastoma RNA, CTLs that lysed neuroblastoma cell lines, including CTLs specific against the widely expressed tumor-antigen survivin, were generated. These findings support a novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies.


Subject(s)
Antigens, Neoplasm/immunology , Antigens, Viral/immunology , B-Lymphocytes/immunology , CD40 Antigens/genetics , Immunotherapy/methods , T-Lymphocytes/immunology , Adult , Age Factors , Animals , B-Lymphocytes/cytology , Cancer Vaccines , Child , Electroporation , Humans , In Vitro Techniques , Influenza, Human/immunology , Influenza, Human/therapy , Lymphocyte Activation , MART-1 Antigen , Mice , NIH 3T3 Cells , Neoplasm Proteins/genetics , RNA, Messenger , T-Lymphocytes/cytology , Transfection
13.
Blood ; 102(6): 2068-73, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12763933

ABSTRACT

This report investigated in vivo turnover kinetics of marrow hematopoietic progenitors and precursors using a recently developed stable isotope-mass spectrometric technique (SIMST). Human subjects were administered a 2-day infusion of 6,6-[2H2]-glucose, a nontoxic stable isotope-labeled form of glucose, which becomes incorporated into DNA of all S-phase cells. The percent [2H2]-glucose incorporated into DNA in the form of [2H2]-deoxyadenosine (%[2H2]-dA enrichment) was determined by gas chromatography-mass spectrometry. The rate constant of replacement of unlabeled by labeled DNA strands (labeling kinetics) was used to calculate population turnover kinetics of CD34+ cells, CD133+ cells, and CD133-CD34+ cells. The observed mean replacement half-life (t1/2) was 2.6 days for CD34+ cells, 2.5 days for CD133-CD34+ cells, and 6.2 days for CD133+ cells. Results from the estimated rate constant of replacement of labeled by unlabeled DNA (delabeling kinetics) also demonstrated slower turnover rates for CD133+ cells than for CD133-CD34+ cells. Although there was a relatively rapid initial decrease in the %[2H2]-dA enrichment, low levels of labeled DNA persisted in CD34+ cells for at least 4 weeks. The results indicate the presence of subpopulations of CD34+ cells with relatively rapid turnover rates and subpopulations with a slower t1/2 of 28 days. Results also demonstrate that in vivo [2H2]-glucose-SIMST is sensitive enough to detect differences in turnover kinetics between erythroid and megakaryocyte lineage cells. These studies are the first to demonstrate the use of in vivo [2H2]-glucose-SIMST to measure in vivo turnover kinetics of subpopulations of CD34+ cells and precursors in healthy human subjects.


Subject(s)
Bone Marrow Cells/cytology , Bone Marrow Cells/metabolism , Hematopoiesis/physiology , S Phase/physiology , AC133 Antigen , Adult , Aged , Aged, 80 and over , Antigens, CD , Antigens, CD34/analysis , Bone Marrow Cells/chemistry , Cell Division/physiology , Cell Lineage/physiology , DNA/metabolism , Deuterium , Erythrocytes/cytology , Female , Glucose/pharmacokinetics , Glycoproteins/analysis , Humans , Kinetics , Male , Megakaryocytes/cytology , Peptides/analysis
14.
Int Immunol ; 14(6): 535-44, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12039905

ABSTRACT

The early activation marker, CD69, is transiently expressed on activated mature T cells and on thymocytes that are undergoing positive or negative selection in the thymus. CD69 is a member of the NK gene complex family of C-type lectin-like signaling receptors; however, its function is unknown. In this report, we describe the characterization of mice that constitutively express high levels of surface CD69 on immature and mature T cells throughout development. Constitutive surface expression of CD69 did not affect T cell maturation, signaling through the TCR or thymocyte selection. However, phenotypically and functionally mature thymocytes accumulated in the medulla of CD69 transgenic mice and failed to be exported from the thymus. The retention of mature thymocytes correlated with transgene dose and CD69 surface levels. These results identify a potential role for CD69 in controlling thymocyte export, and suggest that the transient expression of CD69 on thymocytes and T cells may function to regulate thymocyte and T cell trafficking.


Subject(s)
Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/metabolism , T-Lymphocytes/immunology , Animals , Antigens, CD/genetics , Antigens, Differentiation, T-Lymphocyte/genetics , Cell Differentiation , Cell Movement/immunology , Cell Survival , Humans , Kinetics , Lectins, C-Type , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Phenotype , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/physiology , T-Lymphocytes/cytology , T-Lymphocytes/physiology , Thymus Gland/cytology , Thymus Gland/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...